Michael Yee

UBS | Healthcare

Michael Yee is an analyst from UBS specializing in the Healthcare sector. Ranked #944 out of 4629 analysts, they have issued 45 stock ratings with a success rate of 85.32% and an average return of 17.67%.

Michael Yee has a well-established track record, with 45 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 85.32% and an average return of 17.67%, underscoring their expertise and ability to identify winning opportunities for investors.

#944

Out of 4629

45

Total Ratings

+85.32%

Success Rate

+17.67%

Average Return

Recent Ratings Analysis

BIIB

Apr 22, 2026

Target

$225.00

Current

$190.07

Performance

0.00%

Michael Yee rated BIIB as Buy on Apr 22, 2026, setting a price target of 225. Shares have remained stable near 190.07, leaving the 225 target still in play.

ANAB

Apr 21, 2026

Target

$60.00

Current

$53.55

Performance

3.34%

On Apr 21, 2026, ANAB was given a Buy rating by Michael Yee, with a target price of 60. The stock traded sideways with a 3.34% move, keeping the bullish thesis unresolved.

PFE

Apr 13, 2026

Target

$27.00

Current

$26.78

Performance

-2.05%

PFE received a Neutral rating from Michael Yee on Apr 13, 2026, aiming for 27. Shares remained flat at 26.78, aligning with the neutral rating.

MRK

Apr 13, 2026

Target

$145.00

Current

$112.87

Performance

-6.06%

On Apr 13, 2026, Michael Yee published a Buy outlook on MRK, with a target of 145. Market action contradicted the Buy thesis, as shares slipped to 112.87.

AMGN

Apr 13, 2026

Target

$400.00

Current

$345.92

Performance

-1.11%

Michael Yee on Apr 13, 2026 assigned AMGN a Buy rating, with a price target of 400. The recommendation remains pending validation as shares consolidate around 345.92.

ORKA

Apr 06, 2026

Target

$75.00

Current

$69.68

Performance

23.61%

On Apr 06, 2026, Michael Yee reaffirmed ORKA with a Buy rating, targeting 75. The recommendation was supported by strong follow-through as the stock rose from 69.68 to 69.68.

KOD

Mar 27, 2026

Target

$80.00

Current

$45.19

Performance

22.14%

KOD was rated Buy by Michael Yee on Mar 27, 2026, with a price objective of 80. A bullish response from the market helped close the gap of 34.81 to the target.

SDGR

Mar 17, 2026

Target

$13.00

Current

$12.35

Performance

0.49%

On Mar 17, 2026, Michael Yee initiated coverage on SDGR with a Neutral rating and target of 13. The stock’s lack of movement around 12.35 aligned with a cautious approach.

NUVB

Mar 03, 2026

Target

$10.00

Current

$5.12

Performance

17.43%

Michael Yee issued a Neutral recommendation for NUVB on Mar 03, 2026, price target set at 10. A neutral call gave way to stronger-than-expected performance, closing in on 10.

ACLX

Feb 24, 2026

Target

$115.00

Current

$115.00

Performance

1.10%

On Feb 24, 2026, ACLX was evaluated by Michael Yee, who gave a Neutral rating and target of 115. Hold sentiment was validated by subdued trading with no breakout beyond 115.

GLTO

Feb 17, 2026

Target

$45.00

Current

$25.86

Performance

-13.52%

Michael Yee rated GLTO as Buy on Feb 17, 2026, setting a price target of 45. The stock has underperformed, dropping 13.52% despite the bullish target of 45.

ABBV

Feb 05, 2026

Target

$230.00

Current

$200.49

Performance

-8.46%

On Feb 05, 2026, ABBV was given a Neutral rating by Michael Yee, with a target price of 230. The rating provided protection from downside risk as the stock fell to 200.49.

GILD

Jan 26, 2026

Target

$155.00

Current

$132.90

Performance

-3.54%

GILD received a Buy rating from Michael Yee on Jan 26, 2026, aiming for 155. Price action was muted, as shares hovered around 132.9 despite the bullish outlook.

VRTX

Jan 26, 2026

Target

$545.00

Current

$437.67

Performance

-8.21%

On Jan 26, 2026, Michael Yee published a Buy outlook on VRTX, with a target of 545. Market action contradicted the Buy thesis, as shares slipped to 437.67.

VTYX

Jan 08, 2026

Target

$20.00

Current

$14.00

Performance

1.16%

Michael Yee on Jan 08, 2026 assigned VTYX a Neutral rating, with a price target of 20. The Hold stance reflected consolidation, as shares held near 14.

IDYA

Jan 07, 2026

Target

$50.00

Current

$31.67

Performance

-16.35%

On Jan 07, 2026, Michael Yee reaffirmed IDYA with a Buy rating, targeting 50. Shares slid 16.35% despite the recommendation, highlighting downside risks.

BMY

Jan 07, 2026

Target

$65.00

Current

$58.80

Performance

3.67%

BMY was rated Buy by Michael Yee on Jan 07, 2026, with a price objective of 65. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

LLY

Jan 07, 2026

Target

$1250.00

Current

$921.28

Performance

-16.86%

On Jan 07, 2026, Michael Yee initiated coverage on LLY with a Buy rating and target of 1250. The Buy call has yet to be validated as shares remain 328.72 away from the target.

ALGS

Jan 07, 2026

Target

$20.00

Current

$6.51

Performance

-32.54%

Michael Yee issued a Buy recommendation for ALGS on Jan 07, 2026, price target set at 20. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

ALLO

Jan 07, 2026

Target

$8.00

Current

$2.39

Performance

60.40%

On Jan 07, 2026, ALLO was evaluated by Michael Yee, who gave a Buy rating and target of 8. This case illustrates how a timely bullish rating can translate into tangible gains of 60.40%.

BEAM

Jan 07, 2026

Target

$28.00

Current

$31.69

Performance

9.54%

Michael Yee rated BEAM as Neutral on Jan 07, 2026, setting a price target of 28. Despite the Hold call, shares climbed 9.54% to 31.69, revealing unexpected momentum.

MBX

Jan 07, 2026

Target

$60.00

Current

$33.58

Performance

3.16%

On Jan 07, 2026, MBX was given a Buy rating by Michael Yee, with a target price of 60. The stock traded sideways with a 3.16% move, keeping the bullish thesis unresolved.

OLMA

Jan 07, 2026

Target

$45.00

Current

$16.24

Performance

-40.01%

OLMA received a Buy rating from Michael Yee on Jan 07, 2026, aiming for 45. The rating hasn’t played out as hoped, with the stock trading 40.01% below expectations.

SABS

Jan 07, 2026

Target

$7.00

Current

$3.99

Performance

0.50%

On Jan 07, 2026, Michael Yee published a Buy outlook on SABS, with a target of 7. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 3.99.

SRRK

Jan 07, 2026

Target

$60.00

Current

$47.33

Performance

7.01%

Michael Yee on Jan 07, 2026 assigned SRRK a Buy rating, with a price target of 60. The Buy call aligned well with market performance, producing a gain of 7.01%.

VRDN

Jan 07, 2026

Target

$50.00

Current

$14.33

Performance

-53.12%

On Jan 07, 2026, Michael Yee reaffirmed VRDN with a Buy rating, targeting 50. Shares slid 53.12% despite the recommendation, highlighting downside risks.

ZLAB

Jan 07, 2026

Target

$35.00

Current

$22.87

Performance

20.18%

ZLAB was rated Buy by Michael Yee on Jan 07, 2026, with a price objective of 35. A bullish response from the market helped close the gap of 12.13 to the target.

DNLI

Jan 07, 2026

Target

$25.00

Current

$20.25

Performance

19.47%

On Jan 07, 2026, Michael Yee initiated coverage on DNLI with a Buy rating and target of 25. The stock’s climb of 19.47% since the call highlights the foresight in the rating.

IMCR

Jan 07, 2026

Target

$55.00

Current

$29.98

Performance

-11.20%

Michael Yee issued a Buy recommendation for IMCR on Jan 07, 2026, price target set at 55. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

IVA

Jan 07, 2026

Target

$12.00

Current

$5.25

Performance

2.94%

On Jan 07, 2026, IVA was evaluated by Michael Yee, who gave a Buy rating and target of 12. So far, the Buy call awaits clearer momentum, with shares flat at 5.25.

CRGX

Jul 08, 2025

Target

$5.00

Current

$4.47

Performance

-2.40%

Michael Yee rated CRGX as Hold on Jul 08, 2025, setting a price target of 5. The Hold stance appears justified, as shares hovered around 4.47 with a -2.40% move.

BPMC

Mar 17, 2025

Target

$135.00

Current

$129.46

Performance

40.50%

On Mar 17, 2025, BPMC was given a Buy rating by Michael Yee, with a target price of 135. The stock rallied 40.50% after the rating, narrowing the gap to the target of 135 and validating the bullish stance.

ALXO

Mar 06, 2025

Target

$3.00

Current

$1.70

Performance

29.77%

ALXO received a Buy rating from Michael Yee on Mar 06, 2025, aiming for 3. Momentum has favored the Buy call, with shares climbing from 1.7 to 1.7, rewarding those who trusted the recommendation.

MRNA

Oct 15, 2024

Target

$55.00

Current

$55.60

Performance

-2.98%

On Oct 15, 2024, Michael Yee published a Hold outlook on MRNA, with a target of 55. Sideways action left the Hold view intact, with no major move since 55.6.

AXON

Jul 17, 2024

Target

$385.00

Current

$403.15

Performance

26.86%

Michael Yee on Jul 17, 2024 assigned AXON a Buy rating, with a price target of 385. The Buy call aligned well with market performance, producing a gain of 26.86%.

Frequency Asked Questions

Who is Michael Yee?

Michael Yee is an analyst from UBS specializing in the Healthcare sector.

What is Michael Yee's success rate?

Michael Yee currently has a success rate of +85.32%.

How many ratings has Michael Yee issued?

Michael Yee has issued 45 stock ratings so far.

What is the average return of Michael Yee's calls?

Their stock ratings have generated an average return of +17.67%.

What is Michael Yee's ranking?

Michael Yee is ranked #944 out of 4629 analysts.

What types of ratings does Michael Yee give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Michael Yee?

You can follow Michael Yee by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Michael Yee?

Their latest rating was a Buy on BIIB issued on 2026-04-22.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep